Bergen , Norway, 11 April 2022 -BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the appointment ofCristina Oliva , MD as Chief Medical Officer (CMO), effective25 April 2022 . Cristina joins the senior leadership team heading up clinical development ofBerGenBio's selective AXL inhibitor programs. Cristina is a Board-certified oncologist and brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research Organizations (CROs). Most recently Cristina was Vice President, Oncology and Head ofOncology Centre of Excellence atIQVIA Ltd , where she led the development of decentralized trials and established and led theIQVIA Oncology Global Scientific Advisory Board . Prior to her role at IQVIA, Cristina held senior positions leading oncology development programs forNordic Nanovector ,Takeda Pharmaceuticals ,GlaxoSmithKline and EliLilly .Martin Olin , Chief Executive Officer ofBerGenBio , commented: "I'm delighted to welcome Cristina as our new Chief Medical Officer. Cristina's leadership experience within oncology drug development across big pharma, biotech and CRO environments will be instrumental in executingBerGenBio's development strategy for our AXL inhibitor programs, including our most advanced program bemcentinib, currently in phase II trials." On her appointment as Chief Medical Officer atBerGenBio ,Cristina Oliva , MD, commented:"BerGenBio is on the frontier of developing novel, highly selective AXL inhibitors for the treatment of severe diseases such as oncology and respiratory infections. I'm very excited to joinBerGenBio at this critical phase and look forward to working with the senior leadership team to help further advance its AXL inhibitor programs." Contacts: ForBerGenBio :Martin Olin CEO,BerGenBio ASA ir@bergenbio.comRune Skeie , CFO,BerGenBio ASA rune.skeie@bergenbio.com International Media RelationsMary-Jane Elliott ,Chris Welsh ,Lucy Featherstone Consilium Strategic Communications bergenbio@consilium-comms.com +44 20 3709 5700 AboutBerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in -class selective AXL inhibitor in a broad phase II clinical development programme focused on combination and single agent therapy in cancer and COVID -19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing.BerGenBio is based inBergen, Norway with a subsidiary inOxford, UK . The company is listed on theOslo Stock Exchange (ticker: BGBIO). For more information, visit?www.bergenbio.com Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Suchrisks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source